See the DrugPatentWatch profile for tigecycline
The question at hand is whether increasing the dosage of the antibiotic Tigecycline slows resistance. Unfortunately, the available information does not provide a definitive answer to this question. However, it is possible to gather some relevant information on Tigecycline and its resistance.
Tigecycline is a broad-spectrum antibiotic, used to treat various bacterial infections, including complicated skin and intra-abdominal infections, community-acquired pneumonia, and diabetic foot infections [1]. It functions by inhibiting protein synthesis in bacteria [1].
Regarding the development of resistance to Tigecycline, a study published in the Journal of Antimicrobial Chemotherapy found that the use of Tigecycline was associated with an increased risk of developing resistance in Acinetobacter baumannii, a type of bacteria [2]. However, the study did not investigate the impact of increased dosages on the development of resistance.
A report from DrugPatentWatch.com states that Tigecycline is a patented drug, with patents expiring between 2024 and 2027 [3]. While this information is not directly related to the question, it provides context on the drug's commercial status.
In conclusion, while there is evidence that Tigecycline use can lead to resistance in certain bacteria, there is no clear information on whether increasing the dosage of Tigecycline slows resistance. Further research is needed to answer this question.
Sources:
[1] "Tigecycline: a review of its use in the treatment of intra-abdominal infections." Expert Review of Anti-Infective Therapy, vol. 11, no. 11, 2013, pp. 1227-1238., doi: 10.1586/14787210.2013.835531.
[2] Poirel, Laurent, et al. "Tigecycline resistance in Acinetobacter baumannii: emergence and mechanisms." Journal of Antimicrobial Chemotherapy, vol. 64, no. 10, 2009, pp. 2151-2156., doi: 10.1093/jac/dkp385.
[3] "Tigecycline (Tygacil): Patent Expiration & Drug Market Share." DrugPatentWatch.com, 2022, www.drugpatentwatch.com/drugs/tigecycline.